Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases

    May 26, 2023

    India as a Quad-led biomanufacturing hub

    May 25, 2023

    Manappuram Finance, Rossari Biotech shares trade ex-dividend today

    May 24, 2023
    Facebook Twitter Instagram
    Your Biotech
    • Bio Technology

      Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases

      May 26, 2023

      India as a Quad-led biomanufacturing hub

      May 25, 2023

      Manappuram Finance, Rossari Biotech shares trade ex-dividend today

      May 24, 2023

      Scottish Biotech ILC Therapeutics Signs R&D Partnership With Dechra Pharmaceuticals PLC

      May 23, 2023

      Israeli biotech phenom puts death knell on cancer

      May 22, 2023
    • Pharmaceutical

      Pharma company owner duped of ₹1.1 crore

      November 11, 2022

      Novavax cuts full-year revenue forecast again amid weak demand

      November 10, 2022

      Aurobindo units recall products in US market for manufacturing issues

      November 9, 2022

      AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB

      November 8, 2022

      Trade Spotlight | What should you do with Amara Raja, Sun Pharma Advanced Research, Poly Medicure on Monday?

      November 7, 2022
    Your Biotech
    Home»Pharmaceutical»Fresenius taps pre-dialysis kidney care as drugs promise treatment change
    Pharmaceutical

    Fresenius taps pre-dialysis kidney care as drugs promise treatment change

    yourbiotechBy yourbiotechOctober 5, 2022Updated:November 11, 2022No Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    The world’s largest dialysis company is seeking out kidney disease patients long before they need the most acute form of care as it plans for growth of new drugs that attack the condition’s causes early on.

    For decades, Germany’s Fresenius Medical Care (FMC) (FMEG.DE) has been the biggest player in the $50 billion U.S. market providing dialysis and related machines that help filter out blood toxins for people whose kidneys have failed to function.

    6 minute readOctober 5, 20223:52 PM GMT+5:30Last Updated an hour ago

    Fresenius taps pre-dialysis kidney care as drugs promise treatment change

    By Ludwig Burger

    Diabetes drug Farxiga (dapagliflozin) is displayed at a pharmacy in Provo, Utah, U.S.
    Diabetes drug Farxiga (dapagliflozin) is displayed at a pharmacy in Provo, Utah, U.S.
    Diabetes drug Farxiga (dapagliflozin) is displayed at a pharmacy in Provo, Utah, U.S.

    1/2

    Diabetes drug Farxiga (dapagliflozin) is displayed at a pharmacy in Provo, Utah, U.S. May 28, 2020. REUTERS/George Frey/File Photo

    • Summary
    • Companies
    • New diabetes drugs also shown to slow kidney decline
    • Dialysis company FMC sees impact on its grow outlook
    • Fresenius Medical in push into earlier stages of kidney disease
    • Separate <a href=”/business/healthcare-pharmaceuticals/new-treatments-hold-promise-slowing-kidney-damage-2022-10-05/”>Reuters factbox gives details of new drugs</a>

    FRANKFURT, Oct 5 (Reuters) – The world’s largest dialysis company is seeking out kidney disease patients long before they need the most acute form of care as it plans for growth of new drugs that attack the condition’s causes early on.

    For decades, Germany’s Fresenius Medical Care (FMC) (FMEG.DE) has been the biggest player in the $50 billion U.S. market providing dialysis and related machines that help filter out blood toxins for people whose kidneys have failed to function.

    Advertisement · Scroll to continue

    The company’s 17.6 billion euros ($17.6 billion) in annual revenue has been sustained for decades by high rates of obesity and diabetes, which contribute to kidney damage.

    But the dialysis market is changing as new medications have been shown to dramatically improve the conditions that lead to kidney failure.

    FMC anticipates that the introduction of these drugs could be a drag on its patient population growth for at least some years. To diversify its revenue base it is pushing to expand beyond its core dialysis business into the care of earlier stage kidney disease.

    Latest Updates

    • Pfizer COVID vaccine clears Japan panel for use with young children
    • Factbox: New treatments hold promise of slowing kidney damage
    • Fresenius taps pre-dialysis kidney care as drugs promise treatment change
    • Doctors urge U.S. FDA to add miscarriage management to abortion pill label

    The new drugs include AstraZeneca’s (AZN.L) Farxiga diabetes pill that also delivers benefits for non-diabetics as an approved treatment to slow chronic kidney disease (CKD).

    Germany’s Boehringer Ingelheim and Eli Lilly’s (LLY.N) Jardiance diabetes drug is expected to be used for the same purpose, while Novo Nordisk’s (NOVOb.CO) Wegovy injection offers a new treatment option for obesity. Other similar new treatments such as Eli Lilly’s (LLY.N) Mounjaro are also expected to offer new weight loss options.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous Article8 Best Biotech Stocks to Buy in 2022
    Next Article UPC’s engineering students design a customizable transradial prosthesis using 3D printing
    yourbiotech
    • Website

    Related Posts

    Pharma company owner duped of ₹1.1 crore

    November 11, 2022

    Novavax cuts full-year revenue forecast again amid weak demand

    November 10, 2022

    Aurobindo units recall products in US market for manufacturing issues

    November 9, 2022

    AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB

    November 8, 2022

    Leave A Reply Cancel Reply

    Our Picks

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    About Us
    About Us

    We provide a wide range of customized, integrated B2B and B2C digital marketing services solutions that are ideal for your business.

    We're accepting new partnerships right now.

    Email Us: info@yourmartech.com
    Contact: +1-530-518-1420

    Our Brands
    • Your Martech
    • Your HR Tech
    • Your Fin Tech
    • Your Revenue
    • Your Info Tech
    • Your POS Tech
    • Your Health Tech
    SUBSCRIBE NOW
    Loading
    LinkedIn
    • Privacy Policy
    © 2022 Vigarbiz Inc. Designed by Vigarbiz Media

    Type above and press Enter to search. Press Esc to cancel.